Brought to you by 
MacroGenics nets $62mm through first post-IPO public offering
27 Feb 2014
Executive Summary
In its first public offering since an $85.6mm IPO in October 2013, monoclonal antibody therapeutics developer MacroGenics Inc. netted $62mm through the sale of 1.8mm common shares at $36.50. Selling stockholders also sold 1.2mm shares. Of the total proceeds, MacroGenics plans to put $10-15mm towards development of MGA271, in Phase I with partner Servier for solid tumors; $20-30mm to fund research for two additional oncology candidates based on the company's Dual Affinity Re-Targeting technology; and $5-10mm to expand manufacturing facilities.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Financing
- FOPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
MacroGenics nets $62mm through first post-IPO public offering
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice